SCHEMBL23461528

SCHEMBL23461528

CC1(C(NC(=O)c2ccc3ccccc3c2OCc2ccc(SC(F)(F)F)cc2)C(=O)O)CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 6/20 0.48
▸ RXRA P19793 1/20 0.34
▸ HNF4A P41235 1/20 0.34
▸ PTPRZ1 P23471 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ KCNK2 O95069 1/20 0.33
▸ KCNK10 P57789 1/20 0.33
▸ TACR2 P21452 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ TOP2A P11388 1/20 0.33
▸ TOP2B Q02880 1/20 0.33
▸ SLC6A5 Q9Y345 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ EPHX2 P34913 1/20 0.32
▸ NR1H4 Q96RI1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23460976 0.97 CXCR2 (0.49) CXCR2RXRAHNF4APTPRZ1LMNA
SCHEMBL25548759 0.97 CXCR2 (0.49) CXCR2RXRAHNF4APTPRZ1LMNA
SCHEMBL23460676 0.91 CXCR2 (0.49) CXCR2RXRAHNF4APTPRZ1LMNA
SCHEMBL23461032 0.90 CXCR2 (0.45) CXCR2RXRAHNF4APTPRZ1KCNK2
SCHEMBL38146971 0.90 CXCR2 (0.45) CXCR2RXRAHNF4APTPRZ1KCNK2
SCHEMBL23461920 0.89 CXCR2 (0.59) CXCR2LMNAALDH1A1GAAMAPT
SCHEMBL23460978 0.88 CXCR2 (0.47) CXCR2EPHX2MAOA
SCHEMBL23461432 0.86 CXCR2 (0.46) CXCR2PTPRZ1LMNATACR2ALDH1A1
SCHEMBL25548766 0.86 CXCR2 (0.44) CXCR2LMNATACR2ALDH1A1GAA
SCHEMBL23461082 0.85 CXCR2 (0.60) CXCR2LMNAALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
WO-2021113806-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION (US) 2021-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885RXRA 1850/4885HNF4A 365/4885
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 CXCR2 63/4885RXRA 287/4885HNF4A 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback